NCT05239702

Clinical Study of Targeting CD7 CAR-T Cells in the Treatment of Autoimmune Diseases

A Clinical Study on the Safety and Effectiveness of Targeting CD7 Chimeric Antigen Receptor T Cells in the Treatment of Autoimmune Diseases

• Status: Unknown
• Phase: EARLY_Phase 1
• Study type: Interventional
• Enrollment: 75 (estimated)
• Sponsor: Zhejiang University · Academic / Other
• Sex: All
• Age: —
• Healthy volunteers: Not accepted

Summary

A Clinical Study on the Safety and Effectiveness of Targeting CD7 Chimeric Antigen Receptor T Cells in the Treatment of Autoimmune Diseases

Detailed description

Most patients with autoimmune diseases depend on hormones for life, and when poorly controlled, they are at risk of disability or even death. Studies have found that the abnormal T cell function of patients is closely related to the occurrence and development of the disease. Therefore, reducing the T cells in the patient's body or blocking the function has become the latest breakthrough in treatment. CD7 is a specific antigen on the surface of T cells. CD7 CAR-T can specifically attack T cells and has the potential to cure. In 2019, "Science Translational Medicine" magazine reported that the Marko Radic team demonstrated that CAR-T cells can achieve significant and long-lasting effects in the treatment of systemic lupus erythematosus (SLE) through animal experiments. In 2021, "NEJM" magazine reported the clinical efficacy of CAR-T cells in the treatment of SLE. In the same year, "Journal of Clinical Oncology" reported the clinical efficacy and safety of CD7 CAR-T cells in the treatment of T cell ALL. Based on the current research status, we applied to clinical research on the treatment of refractory autoimmune diseases by targeting CD7 CAR-T cells. The selection criteria is patients with refractory autoimmune diseases. The purpose is to evaluate the safety and effectiveness of targeted CD7 CAR-T cell therapy through this clinical trial study, and to provide clinical evidence and experience reference for the application of CAR-T cell technology in the treatment of refractory autoimmune diseases.

Conditions

• Crohn Disease
• Ulcerative Colitis
• Dermatomyositis
• Still Disease
• Autoimmune Diseases

Interventions

Type	Name	Description
BIOLOGICAL	CD7 CAR T-cells	Each subject receive CD7 CAR T-cells by intravenous infusion

Timeline

• Start date: 2022-02-28
• Primary completion: 2024-12-01
• Completion: 2024-12-01
• First posted: 2022-02-15
• Last updated: 2022-02-15

Locations

1 site across 1 country: China